Eli Lilly 2012 Annual Report Download - page 40

Download and view the complete annual report

Please find page 40 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

28
The following table summarizes our revenue activity in 2012 compared with 2011:
Year Ended Year Ended
December 31, 2012 December 31,
2011 Percent
Change from
Product U.S.(1) Outside U.S. Total Total 2011
(Dollars in millions)
Cymbalta . . . . . . . . . . . . . . . . . . . . . . . . $ 3,917.8 $ 1,076.3 $4,994.1 $ 4,161.8 20
Alimta . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,122.4 1,471.9 2,594.3 2,461.1 5
Humalog. . . . . . . . . . . . . . . . . . . . . . . . . 1,370.9 1,024.6 2,395.5 2,367.6 1
Cialis. . . . . . . . . . . . . . . . . . . . . . . . . . . . 782.2 1,144.6 1,926.8 1,875.6 3
Zyprexa. . . . . . . . . . . . . . . . . . . . . . . . . . 360.4 1,341.0 1,701.4 4,622.0 (63)
Humulin . . . . . . . . . . . . . . . . . . . . . . . . . 592.1 647.0 1,239.1 1,248.8 (1)
Forteo. . . . . . . . . . . . . . . . . . . . . . . . . . . 488.2 662.8 1,151.0 949.8 21
Evista . . . . . . . . . . . . . . . . . . . . . . . . . . . 699.5 310.6 1,010.1 1,066.9 (5)
Strattera. . . . . . . . . . . . . . . . . . . . . . . . . 384.1 237.3 621.4 620.1 —
Effient . . . . . . . . . . . . . . . . . . . . . . . . . . . 339.0 118.2 457.2 302.5 51
Other pharmaceutical products. . . . . . 593.4 1,249.6 1,843.0 2,250.0 (18)
Animal health products. . . . . . . . . . . . . 1,161.8 874.7 2,036.5 1,678.6 21
Total net product sales. . . . . . . . . . . 11,811.8 10,158.6 21,970.4 23,604.8 (7)
Collaboration and other revenue(2) . . . . 501.3 131.7 633.0 681.7 (7)
Total revenue. . . . . . . . . . . . . . . . . . . $ 12,313.1 $ 10,290.3 $ 22,603.4 $ 24,286.5 (7)
1 U.S. revenue includes revenue in Puerto Rico.
2 Collaboration and other revenue consists primarily of royalties for Erbitux and revenue associated with exenatide in the United States.
Sales of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic
pain, generalized anxiety disorder, and in the U.S. for the treatment of chronic musculoskeletal pain and the
management of fibromyalgia, increased 23 percent in the U.S., due to higher prices and, to a lesser extent,
increased demand. Sales outside the U.S. increased 9 percent, driven by increased demand, partially offset by
the unfavorable impact of foreign exchange rates. We will lose effective exclusivity for Cymbalta in the U.S. in
December 2013. Several manufacturers have received tentative approvals to market generic duloxetine, and
we expect generic duloxetine to be introduced in the market immediately following the loss of exclusivity.
While it is difficult to predict the precise impact on Cymbalta sales, we expect the introduction of generics to
result in a rapid and severe decline in our Cymbalta sales, which will have a material adverse effect on results
of operations and cash flows.
Sales of Alimta, a treatment for various cancers, increased 13 percent in the U.S., driven by increased demand
and higher prices. Sales outside the U.S. remained flat, as increased demand was offset by lower prices in
Japan and the unfavorable impact of foreign exchange rates.
Sales of Humalog, our injectable human insulin analog for the treatment of diabetes, decreased 2 percent in
the U.S., due to increased government and commercial rebates as well as the product's removal from a large
formulary in 2012. Sales outside the U.S. increased 6 percent, due to increased demand, partially offset by the
unfavorable impact of foreign exchange rates.
Sales of Cialis, a treatment for erectile dysfunction and benign prostatic hyperplasia (BPH), increased
11 percent in the U.S., driven by increased demand and higher prices. Sales outside the U.S. decreased
2 percent, driven by the unfavorable impact of foreign exchange rates, partially offset by increased demand
and higher prices.
Sales of Zyprexa, a treatment for schizophrenia, acute mixed or manic episodes associated with bipolar I
disorder, and bipolar maintenance, decreased 83 percent in the United States. Sales outside the U.S.
decreased 45 percent. The decreases were due to the loss of patent exclusivity in the U.S. and most major
international markets outside of Japan, partially offset by growth in Japan. Zyprexa sales in Japan were
approximately $585 million in 2012, compared to approximately $540 million in 2011.